Mark Behlke, M.D., Ph.D.Chief Scientific Officer at Integrated DNA Technologies, Inc.
As the Chief Scientific Officer, Dr. Behlke has directed research activities at IDT since joining the company in 1995 with a focus on novel molecular biology applications of oligonucleotide-based technologies. In addition, Dr. Behlke is also a scientific co-founder of Dicerna Pharmaceuticals, located in Boston. Before joining IDT, Dr. Behlke was a Physician Postdoctoral Fellow of the Howard Hughes Medical Institute at the Whitehead Institute, MIT. He was a Resident Physician in Internal Medicine at Brigham and Women’s Hospital, Boston. Dr. Behlke received his M.D. and Ph.D. degrees from Washington University, St. Louis in 1988 and his B.S. degree from the Massachusetts Institute of Technology in 1981. Dr. Behlke is an inventor on over 45 issued US patents, has numerous pending patent applications, and is an author on over 130 scientific publications and book chapters. He is a recognized expert on oligonucleotide-based technologies.